Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624813 | 0.87 | ALDH1A1 (0.51) | ALDH1A1GAANPC1RAB9AFAAH | |
| SCHEMBL5210877 | 0.78 | ADRA2C (0.52) | GAANPC1KMT2AMEN1 | |
| SCHEMBL5211530 | 0.76 | F10 (0.46) | HDAC1HDAC6 | |
| Trifluoroacetic Acid SCHEMBL5212474 | 0.74 | CFD (0.44) | ALDH1A1KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL5210679 | 0.73 | CFD (0.46) | ALDH1A1KMT2A | |
| SCHEMBL1624740 | 0.73 | P2RX7 (0.49) | ALDH1A1EPHX2 | |
| SCHEMBL3455851 | 0.72 | NPC1 (0.61) | ALDH1A1GAANPC1RAB9AFAAH | |
| Hydrochloric Acid SCHEMBL5217194 | 0.71 | ACHE (0.43) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL1622251 | 0.71 | F10 (0.47) | HDAC1HDAC6 | |
| SCHEMBL6988918 | 0.71 | ADRA2C (0.52) | GAANPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | claimed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | claimed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | claimed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | claimed |
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077027-A2 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ALDH1A1 2580/4885GAA 684/4885NPC1 3113/4885 |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | ALDH1A1 3629/4885GAA 548/4885NPC1 1854/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | ALDH1A1 4419/4885GAA 575/4885NPC1 2130/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ALDH1A1 1335/4885GAA 843/4885NPC1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.